SanBio News

SanBio: [Delayed] The publication of an article on the neural activity and network formation promotion of SB623 basic research results.

Jul 9 21:30 ET

SanBio: [Announcements of individual stocks] A paper published in Neuroscience has shown that the main development product, SB623, promotes neural activity and network formation.

Jul 4 02:00 ET

SanBio: [Delayed] The latest information regarding the report on ACUUGO suspension fluid for intracranial transplantation can be found here.

Jun 27 02:00 ET

SanBio: Report on 'ACUUGO Suspension for Cranial Transplantation' which was delayed.

Jun 27 02:00 ET

SanBio: Regarding the partial report on Accugo's intracranial transplantation injection (follow-up report).

Jun 23 22:00 ET

SanBio: Regarding some reports on "Acuugo brain transplantation injection"

Jun 20 02:30 ET

SanBio: Further updated information regarding the manufacturing and sales approval status of the SB623 chronic traumatic brain injury (TBI) program in Japan.

Jun 19 20:30 ET

SanBio: Update on the status of the approval for manufacturing and selling the domestic SB623 chronic traumatic brain injury program.

Jun 19 20:30 ET

SanBio: Interim report

Jun 13 02:02 ET

SanBio: Quarterly Report - 12th Quarter (2024/02/01 - 2024/04/30)

Jun 13 02:01 ET

SanBio: Confirmation letter

Jun 13 02:01 ET

SanBio: Announcements of individual stocks regarding the recording of non-operating income and adjustments for corporate taxes.

Jun 13 02:00 ET

SanBio: Consolidated financial results for the three months ended April 30, 2024 [Japanese Accounting Standards]

Jun 13 02:00 ET

SanBio: 2025 January-term Q1 financial report (Japanese standard) (consolidated).

Jun 13 02:00 ET

SanBio: Announcements of individual stocks regarding recognition of non-operating income and deferred income taxes.

Jun 13 02:00 ET

SanBio: Further updated information regarding the manufacturing and sales approval status of the SB623 chronic traumatic brain injury (TBI) program in Japan.

Jun 12 02:00 ET

SanBio: Status update on the manufacturing approval for the domestic SB623 chronic traumatic brain injury program (continuation report).

Jun 12 02:00 ET

SanBio: Corporate Governance Report 2024/05/14

May 14 03:57 ET

SanBio: Extraordinary Report

Apr 25 02:02 ET

SanBio: Matters relating to business plans and growth potential

Apr 25 02:00 ET